Aligos Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $741 | $965 | $311 | $629 |
Gross Profit | 741 | 706 | 311 | 629 |
EBITDA | -30,783 | -15,419 | -18,733 | -19,892 |
EBIT | -31,481 | -15,678 | -19,243 | -20,563 |
Net Income | -31,537 | -15,863 | 43,088 | -82,150 |
Net Change In Cash | 741 | 965 | 311 | 629 |
Free Cash Flow | -24,538 | -15,613 | -20,952 | -18,431 |
Cash | 41,946 | 18,661 | 73,763 | 36,997 |
Basic Shares | 10,369 | 10,351 | 8,709 | 6,282 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $3,945 | $15,529 | $13,907 | $4,359 |
Gross Profit | 3,945 | 15,529 | 13,907 | 4,359 |
EBITDA | -86,532 | -85,058 | -93,905 | -124,543 |
EBIT | -89,154 | -88,127 | -97,580 | -128,321 |
Net Income | -131,211 | -87,679 | -96,046 | -128,332 |
Net Change In Cash | 3,945 | 15,529 | 13,907 | 4,359 |
Cost of Revenue | -105,518 | -33,963 | ||
Free Cash Flow | -80,873 | -79,016 | -80,332 | -116,554 |
Cash | 36,997 | 135,704 | 81,347 | 186,816 |
Basic Shares | 6,264 | 24,873 | 42,695 | 39,855 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$3.04 |
2025-06-30 | -$1.53 |
2025-03-31 | -$2.11 |
2024-12-31 | -$13.10 |
